Follow
David A. Liebner, MD
David A. Liebner, MD
Assistant Professor of Internal Medicine and Biomedical Informatics, the Ohio State University
Verified email at osumc.edu
Title
Cited by
Cited by
Year
NCCN guidelines insights: soft tissue sarcoma, version 1.2021: featured updates to the NCCN guidelines
M von Mehren, JM Kane, MM Bui, E Choy, M Connelly, S Dry, KN Ganjoo, ...
Journal of the National Comprehensive Cancer Network 18 (12), 1604-1612, 2020
2242020
Soft tissue sarcoma, version 2.2022, NCCN clinical practice guidelines in oncology
M von Mehren, JM Kane, M Agulnik, MM Bui, J Carr-Ascher, E Choy, ...
Journal of the National Comprehensive Cancer Network 20 (7), 815-833, 2022
1222022
Phase 1 study of ipilimumab combined with whole brain radiation therapy or radiosurgery for melanoma patients with brain metastases
NL Williams, EJ Wuthrick, H Kim, JD Palmer, S Garg, H Eldredge-Hindy, ...
International Journal of Radiation Oncology* Biology* Physics 99 (1), 22-30, 2017
1102017
MMAD: microarray microdissection with analysis of differences is a computational tool for deconvoluting cell type-specific contributions from tissue samples
DA Liebner, K Huang, JD Parvin
Bioinformatics 30 (5), 682-689, 2014
902014
Thyroid cancer: pathogenesis and targeted therapy
DA Liebner, MH Shah
Therapeutic advances in endocrinology and metabolism 2 (5), 173-195, 2011
822011
TP53 mutational status is predictive of pazopanib response in advanced sarcomas
K Koehler, D Liebner, JL Chen
Annals of Oncology 27 (3), 539-543, 2016
702016
Treatment of ipilimumab induced Graves’ disease in a patient with metastatic melanoma
U Azmat, D Liebner, A Joehlin-Price, A Agrawal, F Nabhan
Case Reports in Endocrinology 2016, 2016
632016
A network model for dispersion of communicable diseases
L Bian, D Liebner
Transactions in GIS 11 (2), 155-173, 2007
592007
Phase III study of aldoxorubicin vs investigators' choice as treatment for relapsed/refractory soft tissue sarcomas.
SP Chawla, KN Ganjoo, S Schuetze, Z Papai, BA Van Tine, E Choy, ...
Journal of Clinical Oncology 35 (15_suppl), 11000-11000, 2017
492017
Phase I dose escalation and expansion trial to assess the safety and efficacy of ADP-A2M4 SPEAR T cells in advanced solid tumors.
DS Hong, BA Van Tine, AJ Olszanski, ML Johnson, DA Liebner, T Trivedi, ...
Journal of Clinical Oncology 38 (15_suppl), 102-102, 2020
472020
Analysis of BAP1 Germline Gene Mutation in Young Uveal Melanoma Patients
CM Cebulla, EM Binkley, R Pilarski, JB Massengill, K Rai, DA Liebner, ...
Ophthalmic genetics 36 (2), 126-131, 2015
472015
The indications and efficacy of conventional chemotherapy in primary and recurrent sarcoma
DA Liebner
Journal of Surgical Oncology 111 (5), 622-631, 2015
442015
Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial
DS Hong, BA Van Tine, S Biswas, C McAlpine, ML Johnson, AJ Olszanski, ...
Nature medicine 29 (1), 104-114, 2023
432023
A multicenter phase II study of nivolumab+/-ipilimumab for patients with metastatic sarcoma (Alliance A091401): Results of expansion cohorts.
JL Chen, MR Mahoney, S George, CR Antonescu, DA Liebner, ...
Journal of Clinical Oncology 38 (15_suppl), 11511-11511, 2020
422020
Inflammatory myofibroblastic tumor driven by novel NUMA1-ALK fusion responds to ALK inhibition
N Rao, H Iwenofu, B Tang, J Woyach, DA Liebner
Journal of the National Comprehensive Cancer Network 16 (2), 115-121, 2018
312018
Radiation necrosis mimicking rapid intracranial progression of melanoma metastasis in two patients treated with vemurafenib
DA Liebner, SA Walston, R Cavaliere, CJ Powers, E Sauvageau, ...
Melanoma research 24 (2), 172-176, 2014
312014
Angiosarcoma: a rare malignancy with protean clinical presentations
JT Huntington, C Jones, DA Liebner, JL Chen, RE Pollock
Journal of surgical oncology 111 (8), 941-950, 2015
262015
Patterns of major wound complications following multidisciplinary therapy for lower extremity soft tissue sarcoma
ED Miller, X Mo, NT Andonian, KE Haglund, DD Martin, DA Liebner, ...
Journal of surgical oncology 114 (3), 385-391, 2016
252016
NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022: Featured Updates to the NCCN Guidelines
M von Mehren, JM Kane, RF Riedel, JK Sicklick, SM Pollack, M Agulnik, ...
Journal of the National Comprehensive Cancer Network 20 (11), 1204-1214, 2022
232022
A randomized, double‐blind, placebo‐controlled, phase II study of regorafenib versus placebo in advanced/metastatic, treatment‐refractory liposarcoma: results from the sarc024 …
RF Riedel, KV Ballman, Y Lu, S Attia, ET Loggers, KN Ganjoo, ...
The Oncologist 25 (11), e1655-e1662, 2020
21*2020
The system can't perform the operation now. Try again later.
Articles 1–20